LIU Pharmacy and Agilum Partner to Advance Evidence-Based Care

Long Island University Pharmacy (LIU Pharmacy) and Agilum Healthcare Intelligence have joined forces to offer a post-doctoral fellowship program centered on analyzing real-world data and real-world evidence to improve patient outcomes and reduce the total cost of care.

One fellow has been chosen for the inaugural program and will work for two years alongside faculty and staff at LIU Pharmacy’s drug information center to identify areas of unmet need in assessing the efficacy, costs, and outcomes of pharmaceutical drugs.

The fellow and faculty at LIU pharmacy will have access to Agilum’s analytics platform, Comparative Rapid Cycle Analytics (CRCA) P&T, a longitudinal database, to generate real-world evidence identifying the most efficacious patient care regimens. CRCA P&T can compare treatments, drugs, processes, and costs.

Additionally, the Leonardi Institute for Health Analytics and AI has been created and will be housed at LIU Pharmacy's campus in Brooklyn, N.Y.

“The Institute is an evolution of our international drug information center,” Arash T. Dabestani, PharmD, dean of LIU Pharmacy, said in an interview. “The fellow and the Institute will be the lynchpin of our efforts now. We want to standardize and create a formal process for inquiries.”

The CRCA platform, he said, will help LIU Pharmacy’s students and faculty, most of whom sit on P&T committees, to supplement literature reviews with real-world data and help inform monographs and drug class reviews.

“We want to elevate and make more real world the results of monographs, drug utilization evaluations, and class reviews, as well as to pivot the profession of pharmacy and highlight the value of pharmacists on population health management,” Dabestani said.

Agilum’s real-world longitudinal database includes U.S. Census population data representing detailed clinical, financial, demographic, and drug information for tens of millions of patients. The platform compares the drug use and cost data of specific target populations, and filters them by age, gender, disease status, comorbidities, hospital type (urban, rural, academic, medical center, etc.) and objective and statistical similarities.

“P&T has been static in how they develop their drug monographs through public information, clinical research, and other monographs that have been written,” Travis Leonardi, RPh, CEO of Agilum, said in an interview. “This is very dynamic, and it allows health care professionals to deploy analytics using real-world data to implement real changes to P&T for an increased quality of care.”